The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

There is no cure for heart failure and it typically gets worse over time with around half of patients dying within five years ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

The NHS has issued a warning to be vigilant over an uncomfortable symptom in the legs that could indicate a potentially ...

Two papers published in Journal of Orthopaedic Research Spine show the promise of PP353 through preclinical development and ...

(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.

OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...

Weight loss Tiredness Swollen ankles from a build-up of fluid (oedema) Chest pain and coughing up blood - although these are usually signs of another condition, such as chest infection or possibly ...

The NHS is warning people to be vigilant for a potentially fatal symptom that could indicate heart failure. The health body ...

This is a condition known as oedema, which can also impact the feet and ankles, making walking difficult. It might improve in the morning but "get worse later in the day" according to the NHS.